Sort
48,018 grants matching “immunotherapy”
Engineering Anti-Tau Intrabodies that Reduce Tauopathy by Either the Proteasome, Lysosome, or Chaperone Mediated Autophagy
$393,750Gilbert Gallardo · Washington University · R01 · FY2023 · AG
Cellular phenotypic heterogeneity and resistance to radiotherapy in pancreatic adenocarcinoma
$393,750Kenneth L Pitter · Ohio State University · DP5 · FY2024 · OD
Defining the Complosome in Human Cells, Tissues and Disease States
$393,750John Patterson Atkinson · Washington University · R35 · FY2022 · GM
Initiation Of Immune Responses in Chronic Leishmaniasis
$393,750Phillip A. Scott · University Of Pennsylvania · R56 · FY2008 · AI
Cellular phenotypic heterogeneity and resistance to radiotherapy in pancreatic adenocarcinoma
$393,750Kenneth L Pitter · Ohio State University · DP5 · FY2025 · OD
Immune Activating CAR-Modified Antigen Presenting Cells
$393,750Carl Deselm · Washington University · DP5 · FY2022 · OD
Cellular phenotypic heterogeneity and resistance to radiotherapy in pancreatic adenocarcinoma
$393,750Kenneth L Pitter · Ohio State University · DP5 · FY2021 · OD
Cellular phenotypic heterogeneity and resistance to radiotherapy in pancreatic adenocarcinoma
$393,750Kenneth L Pitter · Ohio State University · DP5 · FY2022 · OD
Defining the Complosome in Human Cells, Tissues and Disease States
$393,750John Patterson Atkinson · Washington University · R35 · FY2021 · GM
Engineering Anti-Tau Intrabodies that Reduce Tauopathy by Either the Proteasome, Lysosome, or Chaperone Mediated Autophagy
$393,750Gilbert Gallardo · Washington University · R01 · FY2021 · AG
Engineering Anti-Tau Intrabodies that Reduce Tauopathy by Either the Proteasome, Lysosome, or Chaperone Mediated Autophagy
$393,750Gilbert Gallardo · Washington University · R01 · FY2022 · AG
Immune Activating CAR-Modified Antigen Presenting Cells
$393,750Carl Deselm · Washington University · DP5 · FY2021 · OD
Immune Activating CAR-Modified Antigen Presenting Cells
$393,750Carl Deselm · Washington University · DP5 · FY2020 · OD
Cellular phenotypic heterogeneity and resistance to radiotherapy in pancreatic adenocarcinoma
$393,750Kenneth L Pitter · Ohio State University · DP5 · FY2023 · OD
Mitigating Physical Function Decline in Older Adults with Gastroesophageal Cancer
$393,750Jingran Ji · University Of California Los Angeles · R03 · FY2025 · AG
Defining the Complosome in Human Cells, Tissues and Disease States
$393,748John Patterson Atkinson · Washington University · R35 · FY2023 · GM
Defining the Complosome in Human Cells, Tissues and Disease States
$393,748John Patterson Atkinson · Washington University · R35 · FY2024 · GM
Control of Effector and Memory T Cell Development by Inflammatory Signals
$393,721Susan M Kaech · Yale University · R01 · FY2009 · AI
Core 1: Biospecimen and Translational Pathology Core
$393,701Arivarasan Karunamurthy · University Of Pittsburgh At Pittsburgh · P50 · FY2025 · CA
Safer lung cancer radiotherapy delivery using novel artificial intelligence methods
$393,581Harini Veeraraghavan · Sloan-Kettering Inst Can Research · R01 · FY2022 · CA
ANTIBODY-BASED THERAPY FOR METHAMPHETAMINE ABUSE
$393,542University Of Arkansas Med Scis Ltl Rock · R01 · FY2002 · DA
Engineering Anti-Tau Intrabodies that Reduce Tauopathy by Either the Proteasome, Lysosome, or Chaperone Mediated Autophagy
$393,541Gilbert Gallardo · Washington University · R01 · FY2020 · AG
The role of CEACAM1 in oncogenic B-cell receptor signaling and immunotherapy in mantle cell lymphoma
$393,530Vu Nguyen Ngo · Beckman Research Institute/City Of Hope · R01 · FY2022 · CA
The role of CEACAM1 in oncogenic B-cell receptor signaling and immunotherapy in mantle cell lymphoma
$393,530Vu Nguyen Ngo · Beckman Research Institute/City Of Hope · R01 · FY2023 · CA
Sensitizing high grade serous cancers to immunotherapy through the induction of DNA damage
$393,522Karen McLean · Roswell Park Cancer Institute Corp · R01 · FY2023 · CA